Glaucoma: The least the general practitioner should know
A A Stulting,1
MB ChB, MMed (Ophth), FCS(SA) (Ophth), FRCOphth
(UK), FEACO (Hon), FCMSA (Hon), FACS, FICS;
MB ChB, MMed (Ophth), PhD (HPE)
1 Professor and Head, Department of Ophthalmology, University of the Free State, Bloemfontein, South Africa
Head, Clinical Simulation Unit, School of
Medicine, Faculty of Health Sciences, University of the Free
State, Bloemfontein, South Africa
to: A Stulting (email@example.com)
• What is the definition of glaucoma?
• What is the classification of glaucoma?
• How is glaucoma diagnosed?
• What is the management of glaucoma?
• What is the role of the GP in the management of
Glaucoma has been called the ‘silent thief of the night’
because patients may lose their peripheral vision slowly over a
period of time with no symptoms in many cases. In South Africa,
the prevalence of glaucoma in people older than 40 years of age
is between 4.5% and 5.3%. In whites 1 in 40 people over the age
of 40 years will develop glaucoma (2%). The prevalence in
African-Americans and African-Caribbeans over 40 years of age is
4 times higher.1
Seventy million people world-wide suffer from glaucoma.
Definition of glaucoma
Glaucoma is defined as a progressive, bilateral neuropathy of the optic nerve. It is characterised by:
• raised intra-ocular pressure (IOP) – (normal IOP = 12 - 20 mmHg)
• optic nerve head damage (cupping of the optic disc)
• visual field loss.
Glaucoma can be classified as either congenital or acquired (Table 1).
Table 1. Classification of glaucoma 2
• Primary open-angle glaucoma
• Secondary open-angle glaucoma
• Pre-trabecular glaucoma
• Trabecular glaucoma
• Post-trabecular glaucoma
Aqueous humor is produced by the ciliary body of the eye and it flows through the trabecular meshwork to ensure that the eye is firm so that it can function optically. (Place your finger gently on your eye and then you will feel that the eye is not soft, nor hard, but firm.)
When the trabecular meshwork is obstructed by pigment (e.g. after trauma), red blood cells (e.g. after blunt trauma causing hyphema), inflammatory cells (e.g. after uveitis) or lens material (phacolytic glaucoma), the aqueous humor cannot pass through the trabecular meshwork and the intra-ocular pressure increases.
Pre-trabecular aqueous obstruction may occur if a membrane develops that covers the trabecular meshwork.
In some cases the aqueous humor passes through the iris and sometimes through the uveo-scleral route.
Post-trabecular glaucoma occurs when the trabecular meshwork itself is normal but aqueous outflow is impaired as a result of elevated episcleral venous pressure. This may occur in the following conditions:
• carotid-cavernous fistulae and dural shunts
• Sturge-Weber syndrome
• obstruction of the superior vena cava.
Grading angle width
The grading of angle width is an essential part of the assessment of any patient with glaucomatous or potentially glaucomatous eyes. The main aims are to evaluate the functional status of the angle, its degree of closure and the risk of future closure.3
The following angle structures are identified:
• Schwalbe’s line is the most anterior structure, appearing as an opaque line. Anatomically it represents the peripheral termination of Descemet’s membrane and the anterior limit of the trabecular meshwork.
• The trabecular meshwork extends from Schwalbe’s line to the scleral spur. Gonioscopically, it has a ground-glass appearance.
• The scleral spur. Gonioscopically, it is
situated just posterior to the trabecular meshwork and appears
as a narrow, dense, often shiny, whitish band. It is the site of
attachment of the longitudinal muscle of the ciliary body.
The anterior chamber angle can be classified in the following grades:3
• Grade 4 (35 - 45 degrees): the widest angle (characteristic of myopia and aphakia)in which the ciliary body can still be visualised with ease. It is incapable of closure. (Remember, grade 4 = 4 structures can be seen: Schwalbe’s line, trabecular meshwork, scleral spur, ciliary body.)
• Grade 3 (25 - 35 degrees): the angle is such that at least the scleral spur can be identified. It is also incapable of closure. (Remember, grade 3 = 3 structures can be seen: Schwalbe’s line, trabecular meshwork, scleral spur.)
• Grade 2 (20 degrees) is a moderately narrow angle. Angle closure is possible. (Remember, grade 2 = 2 structures can be seen: Schwalbe’s line and the trabecular meshwork.)
• Grade 1 (10 degrees) is a very narrow angle in which only Schwalbe’s line can be identified. The risk of angle closure is high. (Remember, grade 1 = 1 structure can be seen, only Schwalbe’s line.)
• Grade 0 (0 degrees) is a closed angle due
to irido-corneal contact. (Remember, grade 0 = 0 structures
can be seen in the angle).
Primary angle-closure glaucoma is a condition in which
elevation of IOP occurs as a result of obstruction of aqueous
outflow by partial or complete closure of the angle by the
peripheral iris. Secondary angle-closure glaucoma occurs when
posterior forces push the peripheral iris against the trabecular
meshwork or when anterior forces pull the iris over the
trabecular meshwork (e.g. the contraction of inflammatory
The diagnosis of glaucoma
It is important to enquire about the following risk factors:
• age: older than 40 years (remember: 1 out of every 40 patients above the age of 40 years will develop glaucoma)
• race: black people have a higher risk of glaucoma.
• a positive family history is also a risk factor
for developing glaucoma.
Raised IOP (more than 21 mmHg)
The IOP is measured with a tonometer. The most commonly used tonometer is the Goldmann Applanation tonometer (Fig. 1a), which is attached to a slit-lamp. An area of 3.06 mm diameter is flattened by a prism after local anaesthetic has been instilled in the eye.
The Schiotz tonometer (Fig. 1b) uses the principle of indentation tonometry, in which the extent of corneal indentation by a plunger of known weight is measured.4 This is the recommended instrument in general practice.
Pneumotonometers, such as the Air-Puff tonometer are popular with optometrists as contact is not made with the subject’s eye and topical anaesthesia is not required. The central part of the cornea is flattened by a jet of air. The time required to sufficiently flatten the cornea relates directly to the level of IOP. Its main disadvantage is that it is accurate only within the low-to-middle range.
The ICare tonometer is a new, small hand-held instrument. A
very light probe makesmomentary contact with the cornea and,
because only a very small force is applied to the cornea, a
topical anaesthetic is not required. It can even be used in
babies and small children (Fig. 1c).
Optic nerve evaluation
It is important to know the appearance of the normal optic disc because then the abnormal glaucomatous disc will be more readily diagnosed.
The normal optic disc is characterised as follows (Fig. 2):
• colour: orange-yellow
• vessels: come out centrally out of the optic disc
• cup:disc ratio: usually up to 0.4 (the C/D ratio indicates the diameter of the cup expressed as a fraction of the diameter of the disc)
• edges: well-defined and clearly visible
• shape : round or oval
• size: myopes (larger), hypermetropes (smaller).
The glaucomatous optic disc is characterised as follow (Fig. 3):
• colour: white
• vessels: displaced towards the nasal side
• cup:disc ratio: more than 0.4
• edges: well-defined and clearly visible
• disc haemorrhages
• bayonetting sign (characterised by double angulation of a blood vessel over the edge of the disc): with neuroretinal rim loss between the outer edge of the cup and the optic disc margin, a vessel entering the disc from the retina may angle sharply backwards into the disc and then turn towards the original direction
• neuroretinal rim: thinning and paleness
• laminar dot sign (seen in the base of the optic disc when the neuroretinal rim recedes)
• excavated disc (‘bean pot’).
Visual field testing
A visual field machine, for example, a Humphrey’s perimeter, is
used. Various field defects can be documented, for example a
nasal step of Rönne, a temporal nerve fibre defect, a Bjerrum
arcuate scotoma or a Seidel scotoma.
The angle of the anterior chamber can be assessed by performing
gonioscopy. The examiner, usually the ophthalmologist, uses a
gonio-mirror lens to grade the angle from 1 to 4 (see above).
Management of congenital glaucoma (Fig. 4) 5
• Symptoms: photophobia, lacrimation, blepharospasm.
• Signs: buphthalmos (calf’s eye), corneal diameter ˃12 mm, corneal clouding, white optic disc.
• Treatment: surgery (goniotomy or trabeculotomy).
Management of open-angle glaucoma
Treatment to lower the IOP includes
medical therapy, laser surgery or surgery.
• Topical aqueous suppressants: beta-blockers, adrenergic agents, alpha-2 agonists, carbonic anhydrase inhibitors
• Systemic aqueous suppressants: carbonic anhydrase inhibitors, e.g. Diamox
• Outflow facilitators: topical miotics, prostaglandin agonists.
Administration of eye drops
• The drops should be placed in the inferior fornix of the eye.
• It may be helpful to use a mirror when pulling the eyelids apart.
• Use the ‘no touch’ technique to maintain good hygiene.
• One drop, correctly placed, is sufficient.
• Keep the drops in the fridge: the patient will feel when the cold drop goes into the eye.
• Keep the drops for an average period of 30 days to ensure maximun efficacy.
• If instilling different drops, wait at least 5 minutes between placing the drops in the eye to prevent dilution of the drops.
• Close the punctum so that the drops can stay in
the eye for a longer period.
• argon laser trabeculoplasty (ALT)
• selective laser trabeculoplasty (SLT)
• diode laser trabeculoplasty (DLT).
Argon laser trabeculoplasty (ALT) (Figs 5a-e)
The mechanism of ALT is such that the treated area of trabecular meshwork may shrink, causing stretching of adjacent areas, which leads to increased outflow facilities.
Despite favourable results, laser therapy has not replaced medications as primary therapy in patients with primary open-angle glaucoma (POAG). This was partly due to loss of efficiency over time and the introduction of more effective glaucoma medications, namely prostaglandin analogues.
The role of laser trabeculoplasty is limited and it is used either as adjunctive therapy or as an intermediate step between failed medical therapy and surgical intervention.
Selective laser trabeculoplasty (SLT) 9
SLT is a relatively new procedure which uses a 532 nm Q-switched Nd:YAG laser. This selectively targets melanin pigment in the trabecular meshwork cells, without damaging the non-pigmented structures. It may be safer than ALT as there is no thermal tissue damage. The main advantage is that treatment can be repeated, the laser is portable and the initial results show that it is probably as effective as ALT. This technique may have a place in treating patients in the rural areas of South Africa where compliance or follow up may be a problem.
Diode laser trabeculoplasty (DLT) 10
Diode laser ablation lowers the IOP by destroying part of the secretory ciliary epithelium, thereby reducing aqueous secretion. More than one treatment is usually required for adequate pressure control.
Fig. 5e. The sketch on the left (A) represents the trabecular meshwork with the openings in the meshwork (drawn as squares), while the intended areas of treament are shown as X. The sketch on the right (B) shows that the openings in the trabecular meshwork enlarge at areas away from the fibrotic areas caused by the laser treatment. Aqueous humor can now flow more easily through the enlarged openings in the trabecular meshwork.
Surgical treatment involves either trabeculectomy with or
without mytomicin-C (MMC) (Figs 6 and 7) or valves (Molteno,
Closed-angle glaucoma and its management
• rapidly progressive impairment of vision
• periocular pain and congestion
• nausea and vomiting may occur in severe cases
• transient blurring and haloes around lights.
• circumcorneal redness (in contrast with conjunctivitis, where the redness is mainly in the fornices)
• corneal oedema
• increased IOP
• the pupil is vertically oval and fixed in the
semi-dilated position and is unreactive to both light and
• Initial medical therapy:
• carbonic anhydrase inhibitors (Diamox 500 mg followed by oral acetazolamide 250 mg 4 times daily.
• hyperosmotic agents (oral glycerine given by the ophthalmologist).
• Peripheral Nd: YAG laser iridotomy to re-establish the communication between the anterior and posterior chambers of the eye by making an opening in the peripheral iris.
• A prophylactic laser iridotomy must be performed on the fellow eye to prevent an acute attack in the future.
• Sometimes a surgical peripheral iridectomy must be performed if the iridotomy is too small and not functioning.
• Trabeculectomy is reserved for those patients
who fail to respond or where the angle is chronically closed.
The role of the general practitioner in glaucoma
• Take a good history from the patient:
• Do you have glaucoma?
• Any family member with glaucoma?
• Tell your patients that every person older than 40 years should test their IOP annually.
• Make sure that your patients have regular measurements for IOP.
• Make sure that your glaucoma patients go for regular visual field testing.
• Do regular direct ophthalmoscopy on your patients to detect glaucomatous optic nerve changes.
• Monitor the therapy and make sure that you know the side-effects of the drops your glaucoma patients are taking, namely:
• beta blockers: postural hypotension, bronchospasm
• Diamox: potassium depletion
• topical allergy (Fig. 8).
• Repeat prescribing glaucoma drops – to be reviewed 6-monthly.
• Inform and reassure every glaucoma patient.
• Refer patients to the ophthalmologist for re- assessment, e.g. side-effects of medication, post-glaucoma surgery or red eye.
• Remember that glaucoma is a medical disease
that should be under the control of an ophthalmologist.
1. Fraser S, Wormald R. Epidemiology of glaucoma. In: Yanoff M, Duker JS, eds. Ophthalmology, 2nd ed. St Louis: Mosby, 2009,1413.
2. Kanski JJ, McAllister JA, Salmon JF. Glaucoma. A Colour Manual of Diagnosis and Treatment, 2nd ed. London: Butterworth-Heinemann, 1996:3-5.
3. Kanski JJ, McAllister JA, Salmon JF. Glaucoma. A Colour Manual of Diagnosis and Treatment, 2nd ed. London:Butterworth-Heinemann, 1996:17-19.
4. Kanski JJ, Bowling B. Clinical Ophthalmology: A Systematic Approac., 7th ed. Ediinburgh: Elsevier Saunders, 2011:313-315.
5. Bruce Shields M. Textbook of Glaucoma, 4th ed. Baltimore: Williams and Wilkins, 1998:195-205.
6. Cioffi GA, Duncan J, Girkin CA, et al. Basic and Clinical Science Course, Section 10. Glaucoma. San Francisco: AAO, 2009-2010:188.
7. Cioffi GA, Duncan J, Girkin CA, et al. Basic and Clinical Science Course, Section 10. Glaucoma. San Francisco: AAO, 2010-2011:167-183.
8. Kanski JJ, Bowling B. Clinical Ophthalmology A Systematic Approach, 7th ed. Edinburgh: Elsevier Saunders, 2011:387-388.
9. Kanski JJ, Bowling B. Clinical Ophthalmology A Systematic Approach, 7th ed. Edinburgh: Elsevier Saunders, 2011:388.
10. Kanski JJ, Bowling B. Clinical Ophthalmology A Systematic Approach, 7th ed. Edinburgh: Elsevier Saunders, 2011: 390.
Full text views: 3905